Multiple clinical studies are ongoing to assess whether existing vaccines may afford protection against SARS-CoV-2 infection MESHD through trained immunity. In this exploratory study, we analyze immunization records from 137,037 individuals who received SARS-CoV-2 PCR tests. We find that polio, Hemophilus influenzae type-B (HIB), measles MESHD- mumps MESHD- rubella MESHD (MMR), varicella, pneumococcal conjugate (PCV13), geriatric flu, and hepatitis MESHD hepatitis MESHD hepatitis HP A / hepatitis B MESHD hepatitis HP (HepA-HepB) vaccines administered in the past 1, 2, and 5 years are associated with decreased SARS-CoV-2 infection MESHD rates, even after adjusting for geographic SARS-CoV-2 incidence and testing rates, demographics, comorbidities, and number of other vaccinations. Furthermore, age TRANS, race/ethnicity, and blood SERO group stratified analyses reveal significantly lower SARS-CoV-2 rate among black individuals who have taken the PCV13 vaccine, with relative risk of 0.45 at the 5 year time horizon (n: 653, 95% CI: (0.32, 0.64), p-value: 6.9e-05). These findings suggest that additional pre-clinical and clinical studies are warranted to assess the protective effects of existing non-COVID-19 vaccines and explore underlying immunologic mechanisms. We note that the findings in this study are preliminary and are subject to change as more data becomes available and as further analysis is conducted.